|
341 participants with CSF Aβ40, Aβ42 and pTau, Aβ PET, and tau PET
|
|
Sample size
|
195 (57%)
|
146 (43%)
| |
|
CU/MCI/AD
|
145/46/4
|
74/45/27
| |
|
Age (years)
|
70.4 (9.4)
|
74.7 (10.4)
|
< 0.001
|
|
Education (years)
|
18 (2)
|
16 (3)
|
0.07
|
|
Female (%)
|
115 (59%)
|
78 (53%)
|
0.44
|
|
APOE-ε4 (%)
|
37 (19%)
|
83 (57%)
|
< 0.001
|
|
Aβ PET (Centiloids)
|
4.9 (11.0)
|
71.2 (59.0)
|
< 0.001
|
|
CSF Aβ42
|
1421 (817)
|
653 (377)
|
< 0.001
|
|
CSF Aβ40
|
18,440 (7680)
|
17,770 (6150)
|
0.56
|
|
CSF pTau
|
17.8 (8.2)
|
27.2 (19.9)
|
< 0.001
|
|
CSF pTau/Aβ40
|
0.0010 (0.0002)
|
0.0016 (0.0009)
|
< 0.001
|
|
FTP SUVR (Temporal-metaROI)
|
1.16 (0.08)
|
1.28 (0.27)
|
< 0.001
|
|
aHCV (mm3)
|
7530 (1469)
|
6990 (1750)
|
< 0.001
|
|
PACC
|
0.25 (5.06)
|
−2.33 (11.64)
|
< 0.001
|
|
116 participants with ≥ 2 tau PET scans
|
|
Sample size
|
41 (35%)
|
75 (65%)
| |
|
CU/MCI/AD
|
26/14/1
|
39/25/11
| |
|
FTP visits (median (IQR, range), no.)
|
2.0 (1.0, 2–4)
|
2.0 (1.0, 2–4)
| |
|
FTP follow-up (Median (IQR, range), years)
|
1.8 (1.1, 0.8–3.3)
|
1.2 (1.0, 0.7–3.1)
| |
|
139 participants with ≥ 2 aHCV data
|
|
Sample size
|
64 (46%)
|
75 (54%)
| |
|
CU/MCI/AD
|
42/20/2
|
39/24/12
| |
|
MRI visits (median (IQR, range), no.)
|
2.0 (0, 2–4)
|
2.0 (0.5, 2–4)
| |
|
MRI follow-up (median (IQR, range), years)
|
2.0 (1.0, 0.9–3.8)
|
1.2 (0.9, 0.8–3.2)
| |
|
202 participants with ≥ 2 PACC measurements
|
|
Sample size
|
99 (49%)
|
103 (51%)
| |
|
CU/MCI/AD
|
60/37/2
|
49/36/18
| |
|
PACC visits (median (IQR, range), no.)
|
2 (0, 2–4)
|
2 (1, 2–5)
| |
|
PACC follow-up (median (IQR, range), years)
|
2.0 (1.0, 0.9–3.0)
|
1.1 (1.0, 0.7–4.0)
| |
